術後疼痛(Post-Operative Pain):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Post-Operative Pain - Pipeline Review, H2 2014
◆商品コード:GMDHC5795IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月30日
◆ページ数:165
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における術後疼痛(Post-Operative Pain)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・術後疼痛(Post-Operative Pain)の概要
・術後疼痛(Post-Operative Pain)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・術後疼痛(Post-Operative Pain)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・術後疼痛(Post-Operative Pain)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・術後疼痛(Post-Operative Pain)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Post-Operative Pain – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Post-Operative Pain – Pipeline Review, H2 2014’, provides an overview of the Post-Operative Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Post-Operative Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Operative Pain and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Post-Operative Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Post-Operative Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Post-Operative Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Post-Operative Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Post-Operative Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Post-Operative Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Post-Operative Pain Overview 11
Therapeutics Development 12
Pipeline Products for Post-Operative Pain – Overview 12
Pipeline Products for Post-Operative Pain – Comparative Analysis 13
Post-Operative Pain – Therapeutics under Development by Companies 14
Post-Operative Pain – Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Post-Operative Pain – Products under Development by Companies 20
Post-Operative Pain – Companies Involved in Therapeutics Development 23
A. Menarini Industrie Farmaceutiche Riunite Srl 23
AcelRx Pharmaceuticals, Inc. 24
Adynxx, Inc. 25
AngioChem Inc. 26
Aoxing Pharmaceutical Company, Inc 27
Boehringer Ingelheim GmbH 28
Cara Therapeutics, Inc. 29
Chong Kun Dang Pharmaceutical Corp. 30
Cytogel Pharma, LLC 31
DURECT Corporation 32
Echo Pharmaceuticals B.V. 33
Encore Therapeutics Inc. 34
Flexion Therapeutics, Inc. 35
Galleon Pharmaceuticals 36
GW Pharmaceuticals plc 37
Heron Therapeutics, Inc. 38
Hospira, Inc. 39
Immupharma Plc 40
Laboratorios Del Dr. Esteve S.A. 41
Medtronic, Inc. 42
Ocular Therapeutix, Inc. 43
Omeros Corporation 44
Orbis Biosciences, Inc. 45
Orion Oyj 46
Pfizer Inc. 47
Pharmazz, Inc. 48
PhytoHealth Corporation 49
Recro Pharma, Inc. 50
Rottapharm SpA 51
Takeda Pharmaceutical Company Limited 52
Trevena, Inc. 53
UMeWorld Limited 54
Post-Operative Pain – Therapeutics Assessment 55
Assessment by Monotherapy Products 55
Assessment by Combination Products 56
Assessment by Target 57
Assessment by Mechanism of Action 59
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 65
(bupivacaine hydrochloride + meloxicam) – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
(dexketoprofen trometamol + tramadol hydrochloride) – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
(ketoprofen + amitriptyline + oxymetazoline) – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
(ketorolac tromethamine + phenylephrine) – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
AM-4 – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
ANG-2002 – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
ARX-01 – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
ARX-8028 – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
ARX-8203 – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
AYX-1 – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
BI-1026706 – Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
bupivacaine hydrochloride – Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
bupivacaine hydrochloride SR – Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
buprenorphine hydrochloride ER – Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
centhaquine – Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
CKD-943 – Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
CMX-020 – Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
CR-4056 – Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
CR-845 – Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Cyt-1010 – Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
dexamethasone acetate SR – Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
dexmedetomidine hydrochloride – Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
diclofenac sodium – Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
dronabinol – Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
E-52862 – Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
fadolmidine hydrochloride – Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
FX-007 – Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
GAL-044 – Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
GIBH-1014 – Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
grapiprant – Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
IPP-102199 – Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
ketamine hydrochloride ER – Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
MDT-10013 – Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
nabiximols – Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
nalbuphine hydrochloride – Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
ropivacaine – Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
ropivacaine ER – Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
tilidine hydrochloride – Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
tramadol hydrochloride – Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
TRV-130 – Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
VVZ-149 – Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
Post-Operative Pain – Recent Pipeline Updates 125
Post-Operative Pain – Dormant Projects 153
Post-Operative Pain – Discontinued Products 155
Post-Operative Pain – Product Development Milestones 156
Featured News & Press Releases 156
Nov 17, 2014: Trevena Announces Positive Top-Line Results from Phase 2a/b Study of TRV130 in Acute Postoperative Pain 156
Oct 30, 2014: Omidria Granted Pass-Through Reimbursement Status from CMS 158
Oct 08, 2014: Ocular Therapeutix Completes Enrollment in Phase 3 Sustained Release Dexamethasone Trials for Post-Operative Inflammation and Pain 158
Oct 08, 2014: Trevena Announces Early Completion of Enrollment of Phase 2a/b Study of TRV130 in Postoperative Pain 159
Sep 16, 2014: Trevena Granted Key U.S. Composition of Matter Patent for TRV130 160
Sep 04, 2014: Recro Pharma Provides Clinical Strategy Update Following Interim Analysis for Phase IIb Clinical Trial of Dex-IN 160
Jul 16, 2014: Adynxx Initiates Phase 2 Dose-Ranging Study of AYX1, Lead Compound for the Prevention of Post-Surgical Pain 161
May 14, 2014: Heron Therapeutics Reports Positive Results for Post-Surgical Pain Program 161
May 02, 2014: Trevena Presents Results from Phase 1b Trial of Injectable Analgesic TRV130 at American Society of Pain Annual Meeting 162
May 01, 2014: Trevena Initiates Phase 2 Study of TRV130 in Acute Postoperative Pain 163
Appendix 164
Methodology 164
Coverage 164
Secondary Research 164
Primary Research 164
Expert Panel Validation 164
Contact Us 165
Disclaimer 165

[List of Tables]
Number of Products under Development for Post-Operative Pain, H2 2014 12
Number of Products under Development for Post-Operative Pain - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 15
Number of Products under Development by Companies, H2 2014 (Contd..1) 16
Comparative Analysis by Late Stage Development, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18
Comparative Analysis by Early Stage Development, H2 2014 19
Products under Development by Companies, H2 2014 20
Products under Development by Companies, H2 2014 (Contd..1) 21
Products under Development by Companies, H2 2014 (Contd..2) 22
Post-Operative Pain - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2014 23
Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals, Inc., H2 2014 24
Post-Operative Pain - Pipeline by Adynxx, Inc., H2 2014 25
Post-Operative Pain - Pipeline by AngioChem Inc., H2 2014 26
Post-Operative Pain - Pipeline by Aoxing Pharmaceutical Company, Inc, H2 2014 27
Post-Operative Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2014 28
Post-Operative Pain - Pipeline by Cara Therapeutics, Inc., H2 2014 29
Post-Operative Pain - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014 30
Post-Operative Pain - Pipeline by Cytogel Pharma, LLC, H2 2014 31
Post-Operative Pain - Pipeline by DURECT Corporation, H2 2014 32
Post-Operative Pain - Pipeline by Echo Pharmaceuticals B.V., H2 2014 33
Post-Operative Pain - Pipeline by Encore Therapeutics Inc., H2 2014 34
Post-Operative Pain - Pipeline by Flexion Therapeutics, Inc., H2 2014 35
Post-Operative Pain - Pipeline by Galleon Pharmaceuticals, H2 2014 36
Post-Operative Pain - Pipeline by GW Pharmaceuticals plc, H2 2014 37
Post-Operative Pain - Pipeline by Heron Therapeutics, Inc., H2 2014 38
Post-Operative Pain - Pipeline by Hospira, Inc., H2 2014 39
Post-Operative Pain - Pipeline by Immupharma Plc, H2 2014 40
Post-Operative Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2014 41
Post-Operative Pain - Pipeline by Medtronic, Inc., H2 2014 42
Post-Operative Pain - Pipeline by Ocular Therapeutix, Inc., H2 2014 43
Post-Operative Pain - Pipeline by Omeros Corporation, H2 2014 44
Post-Operative Pain - Pipeline by Orbis Biosciences, Inc., H2 2014 45
Post-Operative Pain - Pipeline by Orion Oyj, H2 2014 46
Post-Operative Pain - Pipeline by Pfizer Inc., H2 2014 47
Post-Operative Pain - Pipeline by Pharmazz, Inc., H2 2014 48
Post-Operative Pain - Pipeline by PhytoHealth Corporation, H2 2014 49
Post-Operative Pain - Pipeline by Recro Pharma, Inc., H2 2014 50
Post-Operative Pain - Pipeline by Rottapharm SpA, H2 2014 51
Post-Operative Pain - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 52
Post-Operative Pain - Pipeline by Trevena, Inc., H2 2014 53
Post-Operative Pain - Pipeline by UMeWorld Limited, H2 2014 54
Assessment by Monotherapy Products, H2 2014 55
Assessment by Combination Products, H2 2014 56
Number of Products by Stage and Target, H2 2014 58
Number of Products by Stage and Mechanism of Action, H2 2014 60
Number of Products by Stage and Route of Administration, H2 2014 62
Number of Products by Stage and Molecule Type, H2 2014 64
Post-Operative Pain Therapeutics - Recent Pipeline Updates, H2 2014 125
Post-Operative Pain - Dormant Projects, H2 2014 153
Post-Operative Pain - Discontinued Products, H2 2014 155

[List of Figures]
Number of Products under Development for Post-Operative Pain, H2 2014 12
Number of Products under Development for Post-Operative Pain - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18
Comparative Analysis by Early Stage Products, H2 2014 19
Assessment by Monotherapy Products, H2 2014 55
Assessment by Combination Products, H2 2014 56
Number of Products by Top 10 Targets, H2 2014 57
Number of Products by Stage and Top 10 Targets, H2 2014 57
Number of Products by Top 10 Mechanism of Actions, H2 2014 59
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 59
Number of Products by Top 10 Routes of Administration, H2 2014 61
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 62
Number of Products by Top 10 Molecule Types, H2 2014 63
Number of Products by Stage and Top 10 Molecule Types, H2 2014 64

【掲載企業】

A. Menarini Industrie Farmaceutiche Riunite Srl
AcelRx Pharmaceuticals, Inc.
Adynxx, Inc.
AngioChem Inc.
Aoxing Pharmaceutical Company, Inc
Boehringer Ingelheim GmbH
Cara Therapeutics, Inc.
Chong Kun Dang Pharmaceutical Corp.
Cytogel Pharma, LLC
DURECT Corporation
Echo Pharmaceuticals B.V.
Encore Therapeutics Inc.
Flexion Therapeutics, Inc.
Galleon Pharmaceuticals
GW Pharmaceuticals plc
Heron Therapeutics, Inc.
Hospira, Inc.
Immupharma Plc
Laboratorios Del Dr. Esteve S.A.
Medtronic, Inc.
Ocular Therapeutix, Inc.
Omeros Corporation
Orbis Biosciences, Inc.
Orion Oyj
Pfizer Inc.
Pharmazz, Inc.
PhytoHealth Corporation
Recro Pharma, Inc.
Rottapharm SpA
Takeda Pharmaceutical Company Limited
Trevena, Inc.
UMeWorld Limited

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[術後疼痛(Post-Operative Pain):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆